Top Tweets for #VisionTrial
Impact of external beam radiotherapy use and timing on clinical outcomes in patients receiving 177Lu-PSMA-617 + best Standard of Care: a secondary analysis from the #VISIONTrial. Presentation by Abigail Pepin, MD @PennCancer. #SNMMI26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/AFVYHm9TPW @SNM_MI
Patients who do not meet the #PSMA PET/CT eligibility criteria used in the #VISIONtrial and who are treated with #LutetiumPSMA do not respond well to treatment with a PSA50RR of 20%. #Biomarker #prostatecancer #theranostics #PETimaging
https://t.co/PzSUB0LO1p
Preliminary #APCCC21 results of Expert Vote: #Consensus Question Nr #78 #LuPSMA #VisionTrial
🎥 All expert session recordings are available online, access w/ your credentials: https://t.co/uOrGrDUYY4
Register for #APCCC22 and get access, too: https://t.co/V6e42WoOwI
#urology
#VISIONtrial Radioligand therapy with #177Lu ☢ in #mCRPC
👥 831 PSMA+
⏳Follow-up 20.9 m
🧐177LuPSMA617 + SC vs SC alone
💡177LuPSMA617
⬆️ imaging based PFS (8.7 vs 3.4 m) HR for progression or ☠ 0.40
⬆️ OS (15.3 vs 11.3 mo) HR for ☠ 0.62
⬆️ AE but QoL was not affected
#snmmi2021 #nuclearmedicine #visiontrial fantastic late breaking session on results Vision trial. Thank you Drs. Morris @morr316 ,El-Haddad @GhassantelHadd1 , Hope @thomashopemd for an excellent informative session. If missed it watch on demand when available
#SNMMI21 Late-Breaking Session Panelists Added! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.
#SNMMI21 Annual Meeting Late-Breaking Session: “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.
#SNMMI21 Annual Meeting Late-Breaking Session! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.
Need to see more about baseline features but it looks like we have another tool for our #ProstateCancer patients 👏👏👏👏 Guided also by #theragnostic @OncoAlert #ASCO21 @DrJaVallejo @CentroGu #Visiontrial
Impressive survival results from the Lu-177 PSMA-617 VISION trial: 38% reduced risk of death and 60% reduced risk of progression. #MedicalResearch #NucMed #PSMA #ProstateCancer https://t.co/0PcfEGDjWE
Today we treated our first 177Lu-PSMA as part of the Endocyte Vision trial @OHSU_NucMed. Very exciting times!! @ErikMittraMD #VisionTrial
OCT guided Athrectomy #pantheris #CVC-PVD #CVC2016 #LimbSalvage #PAD #ACMC #VisionTrial #1tInTheCountry #CathLabTeam
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.7M followers
Taylor Swift
@taylorswift13
82.6M followers
Lady Gaga
@ladygaga
74.1M followers
Virat Kohli
@imvkohli
71.5M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers